Global Blood Therapeutics, Inc. (NASDAQ: GBT) Starts Presentation at 29th Annual ROTH Conference
Global Blood Therapeutics (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The company is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. Additionally, the company is investigating GBT440 for the treatment of hypoxemic pulmonary disorders including idiopathic pulmonary fibrosis. For more information, visit the company’s website at www.globalbloodtx.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company…







